{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:19:52Z","timestamp":1792048792760,"version":"4.4.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013322","name":"European Federation of Pharmaceutical Industries and Associations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.esmoop.2025.105810","type":"journal-article","created":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T23:53:55Z","timestamp":1758153235000},"page":"105810","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Access to novel cancer medicines in Europe: inequities across countries and their drivers"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3309-3181","authenticated-orcid":false,"given":"T.","family":"Hofmarcher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4050-031X","authenticated-orcid":false,"given":"A.","family":"Charalambous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Normanno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-3436","authenticated-orcid":false,"given":"E.","family":"Szmytke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Wilking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2025.105810_bib1","series-title":"Comparator Report on Cancer in Europe 2025 \u2013 Disease Burden, Costs and Access to Medicines and Molecular Diagnostics","author":"Manzano","year":"2025"},{"key":"10.1016\/j.esmoop.2025.105810_bib2","author":"Ferlay"},{"issue":"10125","key":"10.1016\/j.esmoop.2025.105810_bib3","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105810_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5\u2014a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2025.105810_bib5","series-title":"Cancer Care: Assuring Quality to Improve Survival","year":"2013"},{"key":"10.1016\/j.esmoop.2025.105810_bib6","series-title":"Access to High-quality Oncology Care Across Europe","author":"Hofmarcher","year":"2014"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105810_bib7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1093\/cesifo\/ift014","article-title":"Has Medical innovation reduced cancer mortality?","volume":"60","author":"Lichtenberg","year":"2014","journal-title":"CESifo Econ Stud"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105810_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1017\/dem.2018.11","article-title":"The impact of new drug launches on life-years lost in 2015 from 19 types of cancer in 36 countries","volume":"84","author":"Lichtenberg","year":"2018","journal-title":"J Demogr Econ"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105810_bib9","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1080\/13696998.2020.1834403","article-title":"Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016","volume":"23","author":"MacEwan","year":"2020","journal-title":"J Med Econ"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105810_bib10","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41573-023-00723-4","article-title":"Trends in the approval of cancer therapies by the FDA in the twenty-first century","volume":"22","author":"Scott","year":"2023","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.esmoop.2025.105810_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.esmoop.2025.105810_bib12","series-title":"Challenges in Access to Oncology Medicines: Policies and Practices Across the OECD and the EU","author":"Chapman","year":"2020"},{"key":"10.1016\/j.esmoop.2025.105810_bib13","series-title":"Global Oncology Trends 2024: Outlook to 2028","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105810_bib14","series-title":"Access to Oncology Medicines in EU and OECD Countries","author":"Hofmarcher","year":"2024"},{"issue":"12","key":"10.1016\/j.esmoop.2025.105810_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2023.09.1766","article-title":"Surrogate measures and the health technology assessment of cancer drugs in Ireland: a retrospective analysis of EMA cancer drug indication approvals between 2017 and 2022 and recommendations made by the NCPE in Ireland","volume":"26","author":"Assi","year":"2023","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105810_bib16","doi-asserted-by":"crossref","first-page":"889","DOI":"10.3390\/cancers14040889","article-title":"Oncologic drugs approval in Europe for solid tumors: overview of the last 6 years","volume":"14","author":"Falcone","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105810_bib17","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdv249","article-title":"A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)","volume":"26","author":"Cherny","year":"2015","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105810_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100166","article-title":"Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'","volume":"6","author":"Grossmann","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105810_bib19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/annonc\/mdw213","article-title":"ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe","volume":"27","author":"Cherny","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105810_bib20","doi-asserted-by":"crossref","first-page":"e598","DOI":"10.1634\/theoncologist.2019-0523","article-title":"Access to novel drugs for non-small cell lung cancer in Central and Southeastern Europe: a Central European Cooperative Oncology Group Analysis","volume":"25","author":"Cufer","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.esmoop.2025.105810_bib21","series-title":"Comparator Report on Cancer in Europe 2019 \u2013 Disease Burden, Costs and Access to Medicines","author":"Hofmarcher","year":"2019"},{"key":"10.1016\/j.esmoop.2025.105810_bib22","series-title":"Addressing Challenges in Access to Oncology Medicines: Analytical Report","year":"2020"},{"key":"10.1016\/j.esmoop.2025.105810_bib23","series-title":"Exploring the Feasibility of Monitoring Access to Novel Medicines: A Pilot Study in EU Member States","author":"Chapman","year":"2023"},{"key":"10.1016\/j.esmoop.2025.105810_bib24","series-title":"Drug Utilization Research: Methods and Applications","first-page":"315","article-title":"Drug utilization research in the area of cancer drugs","author":"Wilking","year":"2016"},{"key":"10.1016\/j.esmoop.2025.105810_bib26","series-title":"The Future for Health After Brexit","author":"Dayan","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105810_bib27","article-title":"Regulatory policy and pharmaceutical innovation in the United Kingdom after Brexit: initial insights","volume":"9","author":"Hofer","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"10.1016\/j.esmoop.2025.105810_bib28","doi-asserted-by":"crossref","first-page":"e1522","DOI":"10.1200\/OP.21.00909","article-title":"Clinical benefit and expedited approval of cancer drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia","volume":"18","author":"Hwang","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.esmoop.2025.105810_bib29","series-title":"Cancer Care in T\u00fcrkiye in a European Context","author":"Hofmarcher","year":"2022"},{"issue":"7","key":"10.1016\/j.esmoop.2025.105810_bib30","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.healthpol.2019.05.012","article-title":"Alternative access schemes for pharmaceuticals in Europe: towards an emerging typology","volume":"123","author":"Loblova","year":"2019","journal-title":"Health Policy"},{"key":"10.1016\/j.esmoop.2025.105810_bib31","series-title":"Disparities and Challenges in Access to Lung Cancer Diagnostics and Treatment Across Europe","year":"2020"},{"key":"10.1016\/j.esmoop.2025.105810_bib33","series-title":"The Root causes of Unavailability of Innovative Medicines and Delay in Access: Shortening the Wait","year":"2024"},{"issue":"6","key":"10.1016\/j.esmoop.2025.105810_bib34","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.16183","article-title":"Cancer therapy approval timings, review speed, and publication of pivotal registration trials in the US and Europe, 2010\u20132019","volume":"5","author":"Lythgoe","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.esmoop.2025.105810_bib35","series-title":"EFPIA Patients W.A.I.T. Indicator 2023 Survey","author":"Newton","year":"2024"},{"issue":"3","key":"10.1016\/j.esmoop.2025.105810_bib36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.annonc.2024.12.005","article-title":"ESMO Global Consortium Study on the availability, out-of-pocket costs, and accessibility of cancer medicines: 2023 update","volume":"36","author":"Cherny","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105810_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101593","article-title":"Access to novel cancer medicines in four countries in Central and Eastern Europe in relation to clinical benefit","volume":"8","author":"Hofmarcher","year":"2023","journal-title":"ESMO Open"},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2025.105810_bib39","doi-asserted-by":"crossref","first-page":"S467","DOI":"10.1016\/j.jtho.2021.01.805","article-title":"Access disparities and challenges in lung cancer diagnostics and treatment \u2013 a European perspective","volume":"16","author":"Baird","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.esmoop.2025.105810_bib40","series-title":"Cancer Dashboard for Poland - Lung Cancer","author":"Manxhuka","year":"2024"},{"issue":"8","key":"10.1016\/j.esmoop.2025.105810_bib41","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.healthpol.2019.05.021","article-title":"Patterns of alternative access: unpacking the Slovak extraordinary drug reimbursement regime 2012-2016","volume":"123","author":"Loblova","year":"2019","journal-title":"Health Policy"},{"key":"10.1016\/j.esmoop.2025.105810_bib42","article-title":"Overview of external reference pricing systems in Europe","volume":"3","author":"Remuzat","year":"2015","journal-title":"J Mark Access Health Policy"},{"key":"10.1016\/j.esmoop.2025.105810_bib43","series-title":"External Reference Pricing of Medicinal Products: Simulation Based Considerations for Cross Country Coordination","author":"Toumi","year":"2014"},{"key":"10.1016\/j.esmoop.2025.105810_bib44","series-title":"Health at a Glance: Europe 2024: State of Health in the EU Cycle","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105810_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcpo.2022.100362","article-title":"Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe","volume":"34","author":"Hofmarcher","year":"2022","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.esmoop.2025.105810_bib46","series-title":"Diagnosed But Not Treated: How to Improve Patient Access to Advanced NSCLC Treatment in Europe","author":"Hofmarcher","year":"2022"},{"key":"10.1016\/j.esmoop.2025.105810_bib47","series-title":"Cancer Dashboard for Italy \u2013 Access to Cancer Medicines","author":"Pousette","year":"2024"},{"key":"10.1016\/j.esmoop.2025.105810_bib48","series-title":"Costs and Access to Medicines","article-title":"Comparator Report on Cancer in the Nordic Countries \u2013 Disease Burden","author":"Hofmarcher","year":"2019"},{"issue":"10","key":"10.1016\/j.esmoop.2025.105810_bib49","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2025.105810_bib50","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ejca.2022.09.005","article-title":"Access and quality of biomarker testing for precision oncology in Europe","volume":"176","author":"Normanno","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105810_bib51","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41591-022-01717-2","article-title":"Delivering precision oncology to patients with cancer","volume":"28","author":"Mateo","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2025.105810_bib52","series-title":"Vintura. Every Day Counts \u2013 Improving Time to Patient Access to Innovative Oncology Therapies in Europe","year":"2020"},{"issue":"4","key":"10.1016\/j.esmoop.2025.105810_bib55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1080\/14737167.2021.1884546","article-title":"Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications","volume":"21","author":"Godman","year":"2021","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.esmoop.2025.105810_bib56","year":"2018"},{"key":"10.1016\/j.esmoop.2025.105810_bib57","series-title":"Addressing Patient Access Inequalities in Europe","year":"2022"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925016795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702925016795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:00:17Z","timestamp":1772895617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702925016795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2059702925016795"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105810","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Access to novel cancer medicines in Europe: inequities across countries and their drivers","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2025.105810","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"105810"}}